NVLN Logo.jpg
Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice
21 nov. 2017 08h30 HE | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
NVLN Logo.jpg
Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change
09 nov. 2017 08h28 HE | Novelion Therapeutics, Inc.
Company Reiterates FY 2017 Guidance for Total Net Revenues of $135-$145 millionCompany Announces Leadership Change and Search for Chief Executive Officer VANCOUVER, British Columbia, Nov. 09, 2017 ...
NVLN Logo.jpg
Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer
31 oct. 2017 08h30 HE | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
NVLN Logo.jpg
Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D
12 oct. 2017 09h15 HE | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
NVLN Logo.jpg
Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
24 sept. 2017 08h00 HE | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Sept. 24, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of...
NVLN Logo.jpg
Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
15 sept. 2017 08h30 HE | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of...
NVLN Logo.jpg
Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors
11 sept. 2017 08h30 HE | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
NVLN Logo.jpg
Novelion Therapeutics Reports Second Quarter 2017 Financial Results
08 août 2017 07h00 HE | Novelion Therapeutics, Inc.
MYALEPT® Total Net Revenues Increase 28% Over Prior Quarter, Excluding One-Time AdjustmentsGlobal Expansion Plans for Metreleptin Opportunity UnderwayCompany Updates Guidance for FY 2017 Total Net...
NVLN Logo.jpg
Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors
02 août 2017 08h30 HE | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
NVLN Logo.jpg
Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
28 juil. 2017 08h30 HE | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, July 28, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...